Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity-Reference-Cited by-同舟云学术

Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity

Published:2024-05-31 Issue:3 Volume:55 Page:99-113
ISSN:0388-1601
Container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics

Author:

IWASA Takashi¹,YAMA Sachiko¹,HASEGAWA Chihiro¹,YOSHITSUGU Hiroyuki¹,NUSSBAUM Jesse²,WASKIN Hetty²,Ellen WRISHKO Rebecca²

Affiliation:

1. Clinical Pharmacology Development, MSD K.K., Tokyo, Japan

2. MRL, Merck & Co., Inc., Rahway, NJ, USA

Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Link

https://www.jstage.jst.go.jp/article/jscpt/55/3/55_99/_pdf

Reference63 articles.

1. 1) ICH Expert Working Group. ICH harmonised guideline: general considerations for clinical studies E8（R1）. 2021.［https://www.pmda.go.jp/files/000249610.pdf（accessed 2023-11-06）］

2. 2) Hwang TJ, Brawley OW. New federal incentives for diversity in clinical trials. N Engl J Med. 2022; 387（15）: 1347-9. doi: 10.1056/NEJMp2209043.

3. 3) Masters JC, Cook JA, Anderson G, Nucci G, Colzi A, Hellio MP, et al. Ensuring diversity in clinical trials: the role of clinical pharmacology. Contemp Clin Trials. 2022; 118: 106807. doi: 10.1016/j.cct.2022.106807.

4. 4) Takahashi Y. Trend of modality on new drug discovery. Seisakuken-News. 2021; 64: 44-52. ［https://www.jpma.or.jp/opir/news/064/64_6.pdf （accessed 2023-11-06）］（in Japanese）

5. 5) EFPIA MID3 Workgroup; Marshall SF, Burghaus R, Cosson V, Cheung SYA, Chenel M, DellaPasqua O, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol. 2016; 5（3）: 93-122. doi: 10.1002/psp4.12049.